FDA Clearance Tracker · P890019-S006
AB-HAVK RIA ASSAY/ETI-AB-HAVK PLUS
Last checked: Nov 20, 2026Latest source record: Feb 2, 2001 (this decision)Source: openFDAMethods & limitations
Decided
Feb 2, 2001
Approved
Time to decision
120 days
Received Oct 5, 2000. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class II
The decision
- FDA number
- P890019-S006
- Device name
- AB-HAVK RIA ASSAY/ETI-AB-HAVK PLUS
- Applicant
- Diasorin
- Applicant location
- Stillwater, MN
- Received
- Oct 5, 2000
- Decided
- Feb 2, 2001
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P890019
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.3310
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR A CHANGE IN PURIFICATION PROCESS AND STORAGE CONDITIONS OF COMPONENTS OF THE AB-HAVK RIA DEVICE AND THE ETI-AB-HAVK PLUS DEVICE.
Source documents
Other decisions for Diasorin
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260333 · Decided Jun 15, 2026 · 133 days after receipt
Device type: Groups A, C And G Beta-Hemolytic Streptococcus Nucleic Acid Amplification System (PGX) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.